Table 2 Inflammatory markers in sputum and blood at baseline of patients in the efficacy analysis.
| % | ×105 cells/g sputum | Concentration | |
|---|---|---|---|
| Induced sputum | |||
| Total non‐squamous cells | – | 18.0 (2.0–87.1)† | |
| Squamous cells | 10.7 (0–74.4) | – | |
| Neutrophils | 74.4 (46.4–95.4) | 13.0 (1.7–84)† | |
| Macrophages | 20.5 (2.6–47.6) | 3.2 (0.2–21.1)† | |
| Eosinophils | 0.8 (0.02–8.0)† | 0.14 (0.001–4.2)† | |
| Lymphocytes | 1.4 (0–4.6) | 0.24 (0.024–1.87)† | |
| Markers in sputum supernatant | |||
| IL‐8 (ng/ml) | 12.5 (0.49–179.9)† | ||
| Neutrophil elastase (μg/ml) | 3.61 (0.14–120.3)† | ||
| Lactoferrin (μg/ml) | 73.5 (0.8–512.9)† | ||
| ECP (μg/l) | 170.8 (15.6–5767.5)† | ||
| α2‐macroglobulin (ng/ml) | 1345.7 (20.1–15063.04)† | ||
| Blood | |||
| E‐selectin (ng/ml) | 51.7 (33.5–94.6)† | ||
| TNFα (ng/ml) | 8.1 (1.6–37.0)† |
IL, interleukin; ECP, eosinophil cationic protein; TNFα, tumour necrosis factor α.
Data are median or †geometric mean (minimum − maximum).